Jocelyn Kaiser

A promising clinical trial marks another milestone for the CRISPR gene editor

Trump policy denying renewals to Title 42 staff could still threaten in-house research program

NIH will eliminate many peer-review panels and lay off some scientists overseeing them

Stanford health economist Jay Bhattacharya says he’s open to new studies of debunked link between vaccines and autism

Geneticist abruptly announced his resignation over the weekend

Trump policy blocking required notices has frozen reviews of thousands of grants

“Cost efficiency” order could block travel, supplies for labs and patient care

Pause on posting notices had led to scores of canceled meetings

Policy follows firings of tenure-track scientists and suspension of training programs

NIH is appealing loss of some lab leaders among in-house research program while bracing for the next actions from Trump administration

Lawrence Tabak held leadership roles in director’s office for 15 years

Lawsuits argued that cutting “indirect cost” rate would have “devastating” impact on research

Meetings of study sections and closed portion of councils back on track as agency also deals with diversity-related executive orders

NIH spares grants so far, but ‘data apocalypse’ erupts at CDC

Memo from acting director to staff allows some purchasing, and suggests travel and study sections could soon resume

Agency sees pause on purchases, confusion about publishing, and the end of taxpayer-funded security for Anthony Fauci

Researchers facing

Method shrinks time for testing tailored RNA drugs from months to weeks

Two decisions close chapter on controversies over origins of SARS-CoV-2

The biomedical research agency’s 17th director is proud of her initiatives amid tough political landscape